Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

A case for water in the treatment of polycystic kidney disease.

Torres VE, Bankir L, Grantham JJ.

Clin J Am Soc Nephrol. 2009 Jun;4(6):1140-50. doi: 10.2215/CJN.00790209. Epub 2009 May 14. Review.

2.

Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro.

Ye M, Grant M, Sharma M, Elzinga L, Swan S, Torres VE, Grantham JJ.

J Am Soc Nephrol. 1992 Oct;3(4):984-94.

3.

The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease.

Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ.

J Am Soc Nephrol. 2002 Nov;13(11):2723-9.

4.

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.

Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ.

Kidney Int. 2004 Sep;66(3):964-73.

5.

A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.

Barash I, Ponda MP, Goldfarb DS, Skolnik EY.

Clin J Am Soc Nephrol. 2010 Apr;5(4):693-7. doi: 10.2215/CJN.04180609. Epub 2010 Feb 18.

6.
7.

Polycystic kidney disease: etiology, pathogenesis, and treatment.

Martinez JR, Grantham JJ.

Dis Mon. 1995 Nov;41(11):693-765. Review.

PMID:
7587886
8.

Role of vasopressin antagonists.

Torres VE.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1212-8. doi: 10.2215/CJN.05281107. Epub 2008 Apr 23. Review.

9.

Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease.

Grantham JJ, Ye M, Davidow C, Holub B, Sharma M.

J Am Soc Nephrol. 1995 Oct;6(4):1242-9.

10.

Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells.

Pinto CS, Reif GA, Nivens E, White C, Wallace DP.

Am J Physiol Renal Physiol. 2012 Nov 15;303(10):F1412-24. doi: 10.1152/ajprenal.00692.2011. Epub 2012 Sep 5.

11.

Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.

Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP.

Am J Physiol Renal Physiol. 2011 Nov;301(5):F1005-13. doi: 10.1152/ajprenal.00243.2011. Epub 2011 Aug 3.

12.

Rationale for early treatment of polycystic kidney disease.

Grantham JJ.

Pediatr Nephrol. 2015 Jul;30(7):1053-62. doi: 10.1007/s00467-014-2882-8. Epub 2014 Jul 15. Review.

PMID:
25022529
13.

Polycystic kidney disease: huge kidneys, huge problems, huge progress.

Grantham JJ.

Trans Am Clin Climatol Assoc. 1997;108:165-70; discussion 170-2. Review.

14.

Mechanisms of progression in autosomal dominant polycystic kidney disease.

Grantham JJ.

Kidney Int Suppl. 1997 Dec;63:S93-7. Review.

PMID:
9407432
16.

Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease.

Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ.

Am J Kidney Dis. 1997 Nov;30(5):703-9.

PMID:
9370187
17.

Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.

Meijer E, Boertien WE, Zietse R, Gansevoort RT.

Kidney Blood Press Res. 2011;34(4):235-44. doi: 10.1159/000326902. Epub 2011 Jun 21. Review.

18.

Potential pharmacological interventions in polycystic kidney disease.

Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW.

Drugs. 2007;67(17):2495-510. Review.

PMID:
18034588
19.

Evidence for inflammatory and secretagogue lipids in cyst fluids from patients with autosomal dominant polycystic kidney disease.

Grantham JJ, Schreiner GF, Rome L, Grenz L, Joly A.

Proc Assoc Am Physicians. 1997 Jul;109(4):397-408.

PMID:
9220537

Supplemental Content

Support Center